WO2005000040A1 - Infant formula - Google Patents

Infant formula Download PDF

Info

Publication number
WO2005000040A1
WO2005000040A1 PCT/US2004/019738 US2004019738W WO2005000040A1 WO 2005000040 A1 WO2005000040 A1 WO 2005000040A1 US 2004019738 W US2004019738 W US 2004019738W WO 2005000040 A1 WO2005000040 A1 WO 2005000040A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
infant milk
synthetic infant
milk formula
pufas
Prior art date
Application number
PCT/US2004/019738
Other languages
French (fr)
Inventor
Susan E. Carlson
Original Assignee
University Of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Kansas Medical Center filed Critical University Of Kansas Medical Center
Priority to CA002530170A priority Critical patent/CA2530170A1/en
Priority to EP04776829A priority patent/EP1643862A1/en
Priority to MXPA05014190A priority patent/MXPA05014190A/en
Publication of WO2005000040A1 publication Critical patent/WO2005000040A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C1/00—Concentration, evaporation or drying
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to nutritional supplements and formulas, specifically enriched infant formulas that contain a source of long chain polyunsaturated fatty acids ("LC- PUFAs”), a source of sialic acid, and a source of cholesterol.
  • LC- PUFAs long chain polyunsaturated fatty acids
  • sialic acid a source of sialic acid
  • cholesterol a source of cholesterol.
  • the compositions can be used to provide enhanced neurological development, gastrointestinal protection, and immune function in both term and preterm infants.
  • Description of Related Art Human milk has long been recognized as the ideal feeding for term infants because of its nutritional composition and immunologic benefits. Human milk contains all of the nutrients required for the growth and development of the neonate. Three important components of human milk include LC-PUFAs, sialic acids, and cholesterol. See generally Jensen, Handbook of Milk Composition (Academic Press 1995).
  • Human milk contains on average about 50% of energy from fat. This equates to about 67 kcal/dl or about 3.7 g/dl of fat.
  • the majority of fat consists of fatty acids in various glycerides, phospholipids, cholesterol esters, and complex lipids.
  • oleic acid accounts for about 30 to 35 wt% of total fatty acids.
  • about 15-19% of fatty acids are LC-PUFAs. See Putnam et al., The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants, Am J Clin Nutr 1982;36: 106-114.
  • the docosahexaenoic acid and arachidonic acid content ranges from about 0.05% to 2.8 wt% and about 0.3 to 1.0 wt% of total fatty acids, respectively, and decreases post-partum.
  • the mean is about 0.35 wt% (12 mg/dl) and 0.6% (21mg/dl) for docosahexaenoic acid and arachidonic acid, respectively.
  • Sialic acid bound to oligosaccharides accounts for about 75% of the total sialic acid contained in human milk - or about 200 to 1800 mg/L. Most of the sialic acid contained in human milk is found in the form of sialyllactose, an oligosaccharide formed from lactose and sialic acid. The amount of sialic acid in glycoproteins of milk ranges from about 100 to 500 mg/L, declining to about 70 mg/L by 12 weeks of lactation. See Carlson, ⁇ -acetylneuraminic acid concentrations in human milk oligosaccharides and glycoproteins during lactation, Am J Clin Nutr. 1985 Apr;41(4): 720-6.
  • gangliosides which are sialic acid-containing glycolipid, occur mainly as monosialoganglioside 3 (GM3) and disialoganglioside 3 (GD3).
  • GM3 monosialoganglioside 3
  • GD3 disialoganglioside 3
  • the concentration of GM3 in human milk increases, while that of GD3 concentration decreases during lactation.
  • Gangliosides account for about 1% or less of sialic acid in human milk, and decreases substantially within the first few months of lactation. See Nakano et al., Sialic acid in human milk: composition and functions, Acta Paediatr Taiwan 2001 Jan-Feb;42(l):ll-7.
  • Human milk also contains 10-20 mg/dl of sterols, and the majority of that comprises cholesterol.
  • Cholesterol is usually incorporated into infant formulas in minor amounts. For example, one study reported that formulas had cholesterol concentrations 3 to 35 times lower than human milk. See Huisman et al., Triglycerides, fatty acids, sterols, mono- and disaccharides and sugar alcohols in human milk and current types of infant formula milk. Eur J Clin Nutr 1996 Apr;50(4):255-60. Prior work by the inventor has shown that infants fed human milk have significantly higher total plasma cholesterol than infants fed formula and higher combined low-density and very-low-density lipoprotein (“LDL-VLDL”) levels.
  • LDL-VLDL very-low-density lipoprotein
  • U.S. Patent No. 4,303,692 to Gaull teaches an infant formulation containing cholesterol in the range from 20% less to 20% more than the cholesterol concentration found in human milk.
  • human milk contains LC-PUFAs, sialic acid, and cholesterol
  • no infant formula has incorporated the combination of these materials into a single formulation in amounts at or near those of human milk.
  • the present invention is directed to a nutritional supplement which includes LC-PUFAs, and in particular AA and DHA, sialic acid, cholesterol in such a manner.
  • infant formula which contains LC-PUFAs, sialic acid, and cholesterol in amounts that are within the ranges of human milk.
  • infant formula contains LC-PUFAs, sialic acid, and cholesterol in amounts that are within the ranges of human milk.
  • infant formula Those skilled in the art will readily understand what is meant by an infant formula.
  • a typical infant formula contains about 10-35 g/L of protein; 20-50 g/L of lipid; 60-110 g/L of carbohydrates and other various components such as vitamins, minerals, fibers, emulsifiers and the like.
  • infant formula includes so-called "pre-term” and "term” formulas well known to those skilled in the art.
  • U.S. patents are herein incorporated by reference: (1) U.S. Patent No. 6J46,670 to Prieto et al. (2) U.S. Patent No. 6,080,787 to Carlson; (3) U.S. Patent No. 5,492,899 to Masor et al.; (4) U.S. Patent No. 5,021,245 to Borschel et al.; (5) U.S. Pat. No. 5,234,702 to Katz et al.; (6) U.S. Pat. No.
  • Exemplary infant formulas which are commercially available include ENFAMLL, PROSOBEE, PREGESTIMIL, PORTAGEN, NUTRAMIGEN, LOFENALAC, LACTOFREE, GERBER, ALACTA, O-LAC, PROLOSAC (Mead Johnson & Company, Evansville, Indiana), SLMILAC, ISOMIL (Ross Laboratories, Columbus, Ohio), SMA, NURSOY, WYSOY, INFASOY, BONNA MAYORCITOS, STARMIL, (Wyeth Laboratories, Philadelphia, Pa), ALPREM, SOYALAC, FOLLOW-UP, GOODSTART (Nestle Carnation), NENATAL, PREMATALAC, AMMIRON, NUTRLLON, NUTRI-SOJA, FARILON, COW & GATE, CAMELPOW, NENATAL, PEPTI-JR (Nutricia/Cow & Gate, Netherlands), and PREAPTAMLL, APTAMIL, MILUM
  • the synthetic infant formula of the present invention includes a source of LC- PUFAs, source of sialic acid, and source of cholesterol. Each of these three components is preferably contained in the infant formula in amounts corresponding to that of natural human milk.
  • A. Long Chain Poly-Unsaturated Fatty Acid Source Fatty acids are carboxylic acids and are classified based on the length and saturation characteristics of the carbon chain. Short chain fatty acids have 2 to about 6 carbons and are typically saturated. Medium chain fatty acids have from about 6 to about 14 carbons and are also typically saturated. Long chain fatty acids have from 16 to 24 or more carbons and may also be saturated or unsaturated.
  • LC-PUFA long chain polyunsaturated acid
  • AA arachidonic acid
  • ARA arachidonic acid
  • docosahexaenoic acid has a chain length of 22 carbons with 6 double bonds beginning with the third carbon from the methyl end and is thus designated “22:6 n-3".
  • Other important LC-PUFAs are the fatty acids that are precursors in these biosynthetic pathways o f AA and DHA, for example, linoleic (18:2 n-6), ⁇ -linolenic (18:3 n- 6), and dihomo- ⁇ -linolenic (20:3 n-6) acids in the n-6 pathway, and ⁇ -linolenic (18:3 n-3), stearidonic (18:4 n-3), eicosatetraenoic (20:4 n-3), eicosapentaenoic (20:5 n-3), and docosapentaenoic (22:6 n-3) in the n-3 pathway.
  • LC-PUFAs Less prevalent LC-PUFAs are known and listed in Tables I and TV of Carlson et al., U.S. Patent No. 6,080,787 and Table XI of Jensen (pp. 509), which are incorporated by reference.
  • the most preferred LC-PUFAs are the 20 and 22 carbon metabolites, and in particular AA and DHA.
  • Fatty acids are often found in nature as acyl radicals esterified to alcohols.
  • a glyceride is such an ester of one or more fatty acids with glycerol (1,2,3-propanetriol).
  • glycerol backbone molecule If only one position of the glycerol backbone molecule is esterified with a fatty acid, a "mono glyceride” is produced; if two positions are esterified, a “diglyceride” is produced; and if all three positions of the glycerol are esterified with fatty acid a “triglyceride” or “triacylglycerol” is produced.
  • a glyceride is called “simple” if all esterified positions contain the same fatty acid; or “mixed” if different fatty acids are involved.
  • a phospholipid also called a "phosphoglyceride” or "phosphatide” is a special type of glyceride.
  • a phosphoglyceride differs from a triglyceride in having a maximum of two esterified fatty acids, while the third position of the glycerol backbone is esterified to phosphoric acid, becoming a "phosphatidic acid".
  • phosphatidic acid is usually associated with an alcohol which contributes a strongly polar head. Two such alcohols commonly found in nature are choline and enthanolamine.
  • a "lecithin” is a phosphatidic acid associated with the aminoalcohol, "choline”, and is also known as “phosphatidylcholine”. Lecithins vary in the content of the fatty acid component and can be sourced from, for example, eggs and soy.
  • Cephalin phosphatidylethanolamine
  • phosphatidylserine and phosphatidylinositol are other phosphoglycerides. Triglycerides and phospholipids are often classified as long chain or medium chain, according to the fatty acids attached thereto. In human milk, about 98% of the fatty acids are in triglycerides. A source of fatty acids may include any of these forms of glycerides from natural or other origins.
  • Sources of LC-PUFAs include dairy products like eggs and butterfat; marine oils, such as cod, menhaden, sardine, tuna and many other fish; certain animal fats, lard, tallow and microbial oils such as fungal and algal oils as described in detail in U.S. Pat. No. 5,374,657, 5,550,156, and 5,658,767.
  • fish oils are a good source of DHA and they are commercially available in "high EPA” and "low EPA” varieties, the latter having a high DHA:EPA ratio, preferably at least 3:1.
  • Algal oils such as those from dinoflagellates of the class Dinophyceae, notably Crypthecodinium cohnii are also sources of DHA (including DHASCO.TM.), as taught in U.S. Pat. Nos. 5,397,591, 5,407,957, 5,492,938, and 5,711,983.
  • DHA including DHASCO.TM.
  • the genus Mortierella, especially M. alpina, and Pythium insidiosum are good sources of AA, including ARASCO as taught by U.S. Pat. No. 5,658,767 and as taught by Yamada, et al. J. Dispersion Science and Technology, 10(4&5), pp. 561-579 (1989), and Shirunen, et al. Appl. Microbiol.
  • LC-PUFAs may be provided in the composition in the form of esters of free fatty acids; mono-, di- and tri-glycerides; phosphoglycerides, including lecithins; and/or mixtures thereof.
  • LC-PUFAs in the form of phospho lipids, especially phosphatidylcholine.
  • a presently preferred source appears to be egg yolk phospholipids, perhaps due to the high phospholipid and/or phosphatidylcholine content associated with egg derived LC-PUFAs.
  • the infant formula of the present invention includes a source of LC-PUFAs that are within the range of human milk.
  • the LC-PUFAs preferably comprise between about 4.5 to 15% by weight of total fatty acids, and comprise about 35 to 560 mg/dL.
  • the amount of LC-PUFAs in the n-6 pathway and the and n-3 pathway are within the range of human milk.
  • the amount of LC-PUFAs in the n-6 pathway preferably range from about 10-15 wt% total fatty acids.
  • the LC-PUFAs in the n-6 pathway preferably contain less than about 10-15% linoleic acid (18:2n-3) of total fatty acids, and even more preferably between about 10-12 wt%.
  • the formula preferably contains about 150 to 450 mg/dl of LC-PUFAs in the n-6 pathway and about 20 to 80 mg/dl of LC-PUFAs in the n-3 pathway.
  • the 20 and 22 carbon metabolites in the n-6 pathway preferably comprise of total fatty acids.
  • the amount of LC-PUFAs in the n-3 pathway preferably range from about 0.35 to 1.5% wt% total fatty acids.
  • the 20 and 22 carbon metabolites in the n-3 pathway preferably comprise about 0.5 to 1% of total fatty acids.
  • the n-6 and/or n-3 LC-PUFAs may be administered in the form of an intravenous (i.e. parenteral) solution, as can choline and phosphatidylcholine.
  • An intravenous solution will preferably contain effective amounts of the LC-PUFA, the phospholipid and/or the choline in a reasonable daily intake of parenteral solution.
  • compositions will generally include pharmaceutically acceptable vehicles and excipients, such as buffers, preservatives, and the like.
  • the n-6 and/or n-3 LC-PUFAs and the choline and phospholipid may alternatively be administered in the form of an enteral composition.
  • Enteral compositions containing the long chain PUFA, choline or phospholipid may be in the form of a solution or an emulsion of active ingredient; or in a nutritional matrix comprising protein, carbohydrates, other fats, minerals and vitamins.
  • Enteral compositions containing active components may provide either supplemental or complete nutritional support.
  • the concentration of the LC- PUFAs in the enteral composition can range from about 0.35 to 4.0% of AA and DHA depending on the mode of administration and intended purpose. In complete nutritional formulas the concentration may be even lower if enough of the formula is administered to deliver effective amounts of the LC-PUFA.
  • the infant formula preferably provides about 35 to 15% of its energy, and more preferably about 45 to 55% of its energy in the form of fatty acids. More preferably, the invention present comprehends an infant formula containing about 40-50 gms of lipid per liter of formula wherein the lipid comprises a blend of medium chain triglycerides and egg phospholipid.
  • the lipid blend comprises from about 1-40 wt. %, more preferably about 5 to about 30 wt. %, of the egg phospholipid.
  • This embodiment is specifically designed to provide LC-PUFAs selected from n-3 fatty acids and n-6 fatty acids, phospholipids, and/or choline in amounts beneficial to infants.
  • the infant formula contains amounts of AA and DHA that is with in the range of human milk.
  • the DHA content of the infant formula of the present invention ranges between about 0.05% to about 2.8 wt% of the total fatty acids. Even more preferably, DHA content is between 0J5 and 1.5 wt% of the total fatty acids.
  • the DHA content ranges between about 0.35 to 1.2 wt% of the total fatty acids.
  • the infant formula of the present invention contains about 2 to 104 mg/dL of DHA, even more preferably, about 6 to 60 mg/dL of DHA, and still more preferably about 13 to 45 mg/dL of DHA.
  • the AA content of the infant formula of the present invention ranges between about 0.3% to about 1.2 wt% of the total fatty acids. Even more preferably, AA content is between 0.4 and 1.0 wt% of the total fatty acids. Still more preferably, the AA content ranges between about 0.5 to 0.8 wt% of the total fatty acids.
  • the infant formula of the present invention contains about 11 to 44 mg/dL of AA, even more preferably, about 15 to 35 mg/dL of AA, and still more preferably about 23 to 30 mg/dL of AA.
  • the fatty acid composition of the infant formula mimics that of human milk. More specifically, the formula preferably includes about 30 to 50% of the fatty acids as monounsaturated acids. Even more preferably, the formula contains about 30 to 40%) of the fatty acids as oleic acid (18:n-9). Research has suggested that the prolonged feeding of a diet enriched in polyunsaturated acids in early infancy has a significant cholesterol-lowering effect compared to monounsaturates.
  • infants fed formula with higher amounts of linoleic acid (18:2 n-6) have lower cholesterol than those fed formulas high in oleic acid.
  • linoleic acid 18:2 n-6
  • Mize et al. Lipoprotein-cholesterol responses in healthy infants fed defined diets from ages 1 to 12 months: comparison of diets predominant in oleic acid versus linoleic acid, with parallel observations in infants fed a human milk-based diet, J Lipid Res. 1995 Jun;36(6):l 178-87.
  • the present invention preferably includes a suitable balance of monounsaturated/polyunsaturated fats so that the cholesterol is not undesirably lowered.
  • Sialic acid refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N- acetyl-neuraminic acid (2-keto-5-acetamindo-3,5-dideoxy-D-glycero-D- galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA).
  • a second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated.
  • a third sialic acid family member is 2-keto-3- deoxy-nonulosonic acid (KDN) (Nadano et al. (1986) J. Biol. Chem. 261: 11550-11557; Kanamori et al. (1990) J. Biol. Chem. 265: 21811-21819.
  • 9-substituted sialic acids such as a 9-0 — C ⁇ -C 6 acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl- Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac.
  • sialic acid family see, e.g., Varki (1992) Glycobiology 2: 25-40; Sialic Acids: Chemistry,
  • sources of sialic acid include, but are not limited to free sialic acid (such as NANA), as well as sialic acid (such as NANA) complexed to oligosaccharides, glycoproteins, and gangliosides.
  • NANA free sialic acid
  • the sources of sialic acid are comprised predominantly of NANA sources as opposed to other sialic acids, such as Neu5Gc. Even more preferably, NANA sources are exclusively used.
  • Oligosaccharides are polymers of varying number of residues, linkages, and subunits.
  • the basic subunit is a carbohydrate monosaccharide or sugar, such as mannose, glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, and the like.
  • the number of different possible stereoisomeric oligosaccharide chains is enormous. It has been estimated that more than 130 separate neutral and acidic compounds with from 3 to 22 sugars/molecules have been identified in human milk.
  • the sialyated oligosaccharides of the present invention preferably include one or more of the sialic acid containing oligosaccharides listed in Table VI of Jensen, Handbook of Milk Composition (Academic Press 1995), at pp. 293-300, which is hereby incorporated by reference.
  • the present invention can utilize sialic acid any form with sugar moieties, either naturally found or artificially formulated from simple to complex. The simplest is sialylglucose. See Carlson, Human milk nonprotein nitrogen: occurrence and possible functions, Adv Pediatr. 1985;32:43-70. Sialyllactose, which is commercially available from (MoBiTech, Germany), is most preferred.
  • glycoproteins Natural sources of sialydated glycoproteins are well known to those skilled in the art based on of the functional roles of the glycoproteins themselves, e.g., bile salt- stimulated lipase (BSSL), erythropoietin (EPO) and lactoferrin as well as immunoglobulins. These biological glycoproteins are not good sources of NANA, but the sialic acid could be added to a protein source.
  • Gangliosides are a class of glycolipids, often found in cell membranes, that consist of three elements. One or more sialic acid residues are attached to an oligosaccharide or carbohydrate core moiety, which in turn is attached to a hydrophobic lipid (ceramide) structure which generally is embedded in the cell membrane.
  • the ceramide moiety includes a long chain base (LCB) portion and a fatty acid (FA) portion.
  • LCB long chain base
  • FA fatty acid
  • Gangliosides, as well as other glycolipids and their structures in general, are discussed in, for example, Lehninger, Biochemistry (Worth Publishers, 1981) pp. 287-295 and Devlin, Textbook of Biochemistry (Wiley-Liss, 1992). Gangliosides are classified according to the number of monosaccharides in the carbohydrate moiety, as well as the number and location of sialic acid groups present in the carbohydrate moiety.
  • GM Monosialogangliosides are given the designation "GM”, disialogangliosides are designated “GD”, trisialogangliosides “GT”, and tetrasialogangliosides are designated “GQ”. Gangliosides can be classified further depending on the position or positions of the sialic acid residue or residues bound.
  • GM3, GD3, and GM1 are the most preferred gangliosides of the present invention.
  • Sources of gangliosides include deer velvet (actively growing cartilage type tissue in premature deer antlers) and gangliosides isolated from brain (mostly bovine, but theoretically any animal brain could be a source). Gangliosides are commercially available from Larodan Lipids (Sweden). Those skilled in the art will appreciate that gangliosides may also be biosynthesized.
  • the infant formula of the present invention includes a source of sialic acid that is within the range of human milk. More specifically, the infant formula preferably comprises about 200-2300 mg/L of sialic acid, even more preferably about 400 to 700 mg/L of sialic acid, and most preferably about 500 to 600 mg/L sialic acid.
  • the infant formula of the present invention preferably includes sialic acids complexed with oligosaccharides.
  • the oligosaccharide-bound sialic acids preferably comprise between about 50 and 100% of the total source of sialic acids. Even more preferably, the sialic acid complexed with oligosaccharides account for about 70 to 80% of the sialic acid in the formula.
  • the oligosaccharide-bound sialic acids preferably range between about 200 and 1800 mg/L, even more preferably about 400 to 1200 mg/L, and still most preferably about 500 to 600 mg/L.
  • the infant formula of the present invention preferably includes sialic acids complexed with glycoproteins.
  • the glycoprotein-bound sialic acids preferably comprise between about 10% and 50% of the total source of sialic acids. Even more preferably, the sialic acid complexed with glycoproteins account for about 20 to 30% of the sialic acid in the formula.
  • the glycoprotein-bound sialic acid preferably ranges between about 100 to 550 mg/L, and still more preferably between about 200 to 300 mg/L.
  • the infant formula of the present invention preferably ganglioside-bound sialic acids.
  • the gangliosides preferably comprises between about 0% and 5% of the total source of sialic acids. Even more preferably, the gangliosides account for less than 1% of the sialic acid in the formula.
  • the formula preferably contains less than 5 mg/L gangliosides.
  • the present invention also includes a source of cholesterol well known to those skilled in the art.
  • cholesterol is found in eggs, beef tallow, dairy products, meat, poultry, fish, and shellfish.
  • Egg yolks and organ meats are high in dietary cholesterol.
  • Fish generally contains less cholesterol 10 than other meats, but some shellfish is high in cholesterol content.
  • Sources of cholesterol also include precursors such as squalene, lanosterol, dimethylsterol, methostenol, lathosterol, and desmosterol.
  • the infant formula of the present invention comprises about 10 to 40 mg/dl cholesterol. Even more preferably, the present invention comprises about 15 to 26 mg/dl 15 cholesterol.
  • the synthetic infant formula of the present invention may be made de novo using methods well known to those skilled in the art.
  • the infant formula may be made by modifying an existing infant formula to contain LC-PUFAs, sialic acids, and cholesterol within the range of human milk.
  • 20 EXAMPLES Prophetic Example 1 Egg yolk cholesterol, N-acetylneuraminic acid, docosahexaenoic acid and arachidonic acid obtained from commercial sources are used in the following Examples. Those skilled in the art will appreciate that procedures for isolating cholesterol and N- 25 acetylneuraminic acid from traditional food sources exist (for example from egg yolk and mammalian milk, respectively) and could be modified to produce these components in the quantities necessary for bulk addition to infant formula as specified herein.
  • Docosahexaenoic acid and arachidonic acid from fish, egg yolk lipids, egg yolk phospholipids and single cell oil sources are commercially available from a number of sources and are well known to those 30 skilled in the art.
  • egg yolk cholesterol and N-acetylneuraminic acid would be added to a cows-milk-derived formula that is currently marketed and that contains at least 0.35% docosahexaenoic acid (Martek Biosciences) and 0.5% arachidonic acid (Martek Biosciences) of total fatty acids from single cell oil sources.
  • Cholesterol would comprise 200 mg/L of formula.
  • N-acetylneuraminic acid would be added in amounts of 500 mg/L as the free sugar.
  • cholesterol isolated from egg yolk and siallylactose from cows' milk would be added to a currently marketed formula that contains docosahexaenoic acid and arachidonic acid as 0.35 and 0.5% of total fatty acids, respectively.
  • Cholesterol would contribute 200 mg/L formula and siallylactose would contribute 500 mg sialic acid/L.
  • Lactose in the formula is decreased in the amount of lactose added via siallylactose per liter.
  • human milk contains cholesterol, LC-PUFAs, and sialic acid. All three of these components are found in the plasma membranes of cells. In particular all three compounds are present in regions of the membrane known as lipid rafts.
  • lipid rafts are operationally defined as regions of the plasma membrane that are not soluble in detergent. These microdomains on the plasma membrane are rich in cholesterol (-50%), sphingolipids, including some gangliosides( ⁇ 10-20%) and phospholipids.
  • proteins are enriched in lipid rafts. These include caveolins, flotilins, GPI-linked proteins, low molecular weight and heterotrimeric G proteins, src family kinases, EGF receptors,, platelet- derived growth factor (PDGF) receptors, endothelin receptors, MAP kinase, protein kinase C etc.
  • PDGF platelet- derived growth factor
  • lipid rafts likely have both long-term and short-term consequences for the developing organism. These components likely influence the cell function, especially involving neutotransmitters, proteins involved in signal transduction, and proteins that function as enzymes in catalyzing the metabolic reactions.
  • the present invention contemplates that all three components are thought to be important for signaling between cells of different types, such as myelination of neurons by oligodendrocytes.
  • the present invention therefore predicts that alteration in LC-PUFAs, cholesterol in sialic acid can affect membranes in any organ or cell of the body and therefore function. For example changes in renal brush-border membrane cholesterol can suppress or promote domains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dairy Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nutritional supplement comprising an infant milk formula having long chain poly unsaturated fatty acids, sialic acids, and cholesterol.

Description

INFANT FORMULA
Field of the Invention This invention relates to nutritional supplements and formulas, specifically enriched infant formulas that contain a source of long chain polyunsaturated fatty acids ("LC- PUFAs"), a source of sialic acid, and a source of cholesterol. Among other things, the compositions can be used to provide enhanced neurological development, gastrointestinal protection, and immune function in both term and preterm infants. Description of Related Art Human milk has long been recognized as the ideal feeding for term infants because of its nutritional composition and immunologic benefits. Human milk contains all of the nutrients required for the growth and development of the neonate. Three important components of human milk include LC-PUFAs, sialic acids, and cholesterol. See generally Jensen, Handbook of Milk Composition (Academic Press 1995). Human milk contains on average about 50% of energy from fat. This equates to about 67 kcal/dl or about 3.7 g/dl of fat. The majority of fat consists of fatty acids in various glycerides, phospholipids, cholesterol esters, and complex lipids. Typically oleic acid accounts for about 30 to 35 wt% of total fatty acids. Typically, about 15-19% of fatty acids are LC-PUFAs. See Putnam et al., The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants, Am J Clin Nutr 1982;36: 106-114. Of these, the docosahexaenoic acid and arachidonic acid content ranges from about 0.05% to 2.8 wt% and about 0.3 to 1.0 wt% of total fatty acids, respectively, and decreases post-partum. Worldwide, the mean is about 0.35 wt% (12 mg/dl) and 0.6% (21mg/dl) for docosahexaenoic acid and arachidonic acid, respectively. See generally Jensen, Handbook of Milk Composition, at Table XI, pp. 509-510 (Academic Press 1995); Tomarelli, Suitable fat formulations for infant feeding in Dietary Fat Requirements in Health and Development, (J. Beare-Rodgers ed.), American Oil Chemists Society; Harzer et al., Changing patterns of human milk lipids in the course of the lactation and during the day, Am J Clin Nutr 1983 Apr;37(4):612-21 ; Boersma et al., Vitamin E, lipid fractions, and fatty acid composition of colostrum, transitional milk, and mature milk: an international comparative study, Am J Clin Nutr 1991 May;53(5): 1197-204. In human milk, sialic acid is present in different sialoglycoconjugate compounds such as oligosaccharides, glycolipids and glycoproteins, not in a free form. Human milk contains about 0.3-1.5 mg/ml of sialic acid. Sialic acid bound to oligosaccharides accounts for about 75% of the total sialic acid contained in human milk - or about 200 to 1800 mg/L. Most of the sialic acid contained in human milk is found in the form of sialyllactose, an oligosaccharide formed from lactose and sialic acid. The amount of sialic acid in glycoproteins of milk ranges from about 100 to 500 mg/L, declining to about 70 mg/L by 12 weeks of lactation. See Carlson, Η-acetylneuraminic acid concentrations in human milk oligosaccharides and glycoproteins during lactation, Am J Clin Nutr. 1985 Apr;41(4): 720-6. In milk, gangliosides, which are sialic acid-containing glycolipid, occur mainly as monosialoganglioside 3 (GM3) and disialoganglioside 3 (GD3). The concentration of GM3 in human milk increases, while that of GD3 concentration decreases during lactation. Gangliosides account for about 1% or less of sialic acid in human milk, and decreases substantially within the first few months of lactation. See Nakano et al., Sialic acid in human milk: composition and functions, Acta Paediatr Taiwan 2001 Jan-Feb;42(l):ll-7. Human milk also contains 10-20 mg/dl of sterols, and the majority of that comprises cholesterol. See Jensen, Lipids in human milk— Composition and fat soluble vitamins, in Textbook of Gastroenterology in Infancy (Lebenthal el., 2d ed), pp. 57-208; Kallio et al., Cholesterol and its precursors in human milk during prolonged exclusive breastfeeding, Am J Clin Nutr 1989 Oct;50(4):782-5. One study reported a mean cholesterol content of 36.0 mg/dl between 0 and 4 days post-partum, 19.7 mg/dl between days 5 and 9, and 19.0 mg/dl between days 10 and 30. See Boersma et al, Vitamin E, lipid fractions, and fatty acid composition of colostrum, transitional milk, and mature milk: an international comparative study, Am J Clin Nutr 1991 May;53(5):l 197-204. LC-PUFAs, sialic acid, and cholesterol have been incorporated to some extent in infant milk formulas. See generally Jensen, Handbook of Milk Composition (Academic Press 1995), at pp. 835-855. Applicant is a co-mventor of U.S. Patent No. 6,306,908, which illustrates that LC-PUFAs are useful in reducing necrotizing enterocolitis. Nevertheless, whether or not formulas designed for the preterm infant should be supplemented with LC- PUFAs, including arachidonic acid ("AA", 20:4n-6) and/or docosahexaenoic acid ("DHA", 22:6n-3) has become one of the most controversial issues in infant nutrition today. See generally Carlson, U.S. Patent No. 6,306,908. Studies have also shown that low levels of sialic acids are incorporated to into infant formula. See Carlson, ^-acetylneuraminic acid concentrations in human milk oligosaccharides and glycoproteins during lactation, Am J Clin Nutr. 1985 Apr;41(4):720-6; Martin-Sosa et al., Sialyloligosaccharides in human and bovine milk and in infant formulas: variations with the progression of lactation, J Dairy Sci 2003 Jan;86(l):52-9 (finding that infant formulas did not contain significant amounts of sialyloligosaccharides); Wang et al., Concentration and distribution of sialic acid in human milk and infant formulas, Am J Clin Nutr 2001 Oct;74(4):510-5 (finding that the sialic acid content of most formulas was <25% of that found in mature human milk); Pan XL & Izumi, Variation of the ganglioside compositions of human milk, cow's milk and infant formulas, Early Hum Dev 2000 Jan;57(l):25-31 (finding that the major ganglioside in the later human milk, GM3 (27.7%), was only a minor component in the colostrum, cow's milk and infant formulas (3.3, 2.8 and 0.4-2.6%, respectively)). Researchers have theorized that supplementation with sialic acid- containing glycoconjugates of infant formulas would be recommended for the first days after delivery when breast-feeding is not possible. The theory was that the reference standard for optimal nutrition in the early months of infancy is human milk. See Carlson, Human milk nonprotein nitrogen: occurrence and possible functions, Adv Pediatr. 1985;32:43-70; Sanchez-Diaz, A critical analysis of total sialic acid and sialoglycoconjugate contents of bovine milk-based infant formulas, J Pediatr Gastroenterol Nutr 1997 Apr;24(4):405-10. However, to the inventor's knowledge, no such products have ever been produced which contain such amounts of sialic acids. Cholesterol is usually incorporated into infant formulas in minor amounts. For example, one study reported that formulas had cholesterol concentrations 3 to 35 times lower than human milk. See Huisman et al., Triglycerides, fatty acids, sterols, mono- and disaccharides and sugar alcohols in human milk and current types of infant formula milk. Eur J Clin Nutr 1996 Apr;50(4):255-60. Prior work by the inventor has shown that infants fed human milk have significantly higher total plasma cholesterol than infants fed formula and higher combined low-density and very-low-density lipoprotein ("LDL-VLDL") levels. See Carlson et al., Effect of infant diets with different polyunsaturated to saturated fat ratios on circulating high-density lipoproteins, J Pediatr Gastroenterol Nutr. 1982;l(3):303-9. U.S. Patent No. 4,303,692 to Gaull teaches an infant formulation containing cholesterol in the range from 20% less to 20% more than the cholesterol concentration found in human milk. Although human milk contains LC-PUFAs, sialic acid, and cholesterol, no infant formula has incorporated the combination of these materials into a single formulation in amounts at or near those of human milk. The present invention is directed to a nutritional supplement which includes LC-PUFAs, and in particular AA and DHA, sialic acid, cholesterol in such a manner. Brief Summary of the Invention It is another object of the present invention to provide a nutritional supplement. It is a further object of the present invention to provide an infant formula which contains LC-PUFAs, sialic acid, and cholesterol in amounts that are within the ranges of human milk. Detailed Description of the Preferred Embodiment The present invention relates to an "infant formula." Those skilled in the art will readily understand what is meant by an infant formula. When diluted or reconstituted, if initially in concentrate or powder form, to the ready to feed state, a typical infant formula contains about 10-35 g/L of protein; 20-50 g/L of lipid; 60-110 g/L of carbohydrates and other various components such as vitamins, minerals, fibers, emulsifiers and the like. The term "infant formula" includes so-called "pre-term" and "term" formulas well known to those skilled in the art. For purposes of understanding the components of an infant formula and methods for its production, the following U.S. patents are herein incorporated by reference: (1) U.S. Patent No. 6J46,670 to Prieto et al. (2) U.S. Patent No. 6,080,787 to Carlson; (3) U.S. Patent No. 5,492,899 to Masor et al.; (4) U.S. Patent No. 5,021,245 to Borschel et al.; (5) U.S. Pat. No. 5,234,702 to Katz et al.; (6) U.S. Pat. No. 5,602,109 to Masor et al.; (7) U.S. Patent No. 5,492,938 to Kyle et al.; (8) U.S. Pat. No. 4,670,268 to Mahmoud; (9) U.S. Patent No. 4,670,285 to Clandinin et al; (10) U.S. Patent No. 4,303,692 to Gaull; (11) U.S. Patent No. 4,216,236 to Mueller et al; (12) U.S. Patent No. 3,798,339 to Peng, (13) U.S. Patent No. 3,542,560 to Tomarelli et al.; and (14) U.S. Patent No. 2,694,640 to Gyorgy. Exemplary infant formulas which are commercially available include ENFAMLL, PROSOBEE, PREGESTIMIL, PORTAGEN, NUTRAMIGEN, LOFENALAC, LACTOFREE, GERBER, ALACTA, O-LAC, PROLOSAC (Mead Johnson & Company, Evansville, Indiana), SLMILAC, ISOMIL (Ross Laboratories, Columbus, Ohio), SMA, NURSOY, WYSOY, INFASOY, BONNA MAYORCITOS, STARMIL, (Wyeth Laboratories, Philadelphia, Pa), ALPREM, SOYALAC, FOLLOW-UP, GOODSTART (Nestle Carnation), NENATAL, PREMATALAC, AMMIRON, NUTRLLON, NUTRI-SOJA, FARILON, COW & GATE, CAMELPOW, NENATAL, PEPTI-JR (Nutricia/Cow & Gate, Netherlands), and PREAPTAMLL, APTAMIL, MILUMLL, LEMIEL, NEKTARMIL, HN-25, GES-45, SOM, PREGOMLN (Milupa, Germany). The synthetic infant formula of the present invention includes a source of LC- PUFAs, source of sialic acid, and source of cholesterol. Each of these three components is preferably contained in the infant formula in amounts corresponding to that of natural human milk. A. Long Chain Poly-Unsaturated Fatty Acid Source Fatty acids are carboxylic acids and are classified based on the length and saturation characteristics of the carbon chain. Short chain fatty acids have 2 to about 6 carbons and are typically saturated. Medium chain fatty acids have from about 6 to about 14 carbons and are also typically saturated. Long chain fatty acids have from 16 to 24 or more carbons and may also be saturated or unsaturated. In longer fatty acids there may be one or more points of unsaturation, giving rise to the terms "monounsaturated" and "polyunsaturated", respectively. As used herein, the term "long chain polyunsaturated acid" (LC-PUFA) means a fatty acid of twenty carbon atoms or more having at least two carbon-carbon double bonds (polyunsaturated). The number and position of double bonds in fatty acids are designated by a convention of nomenclature. For example, arachidonic acid ("AA" or "ARA") has a chain length of 20 carbons and 4 double bonds beginning at the sixth carbon. As a result, it is referred to as "20:4 n-6". Similarly, docosahexaenoic acid ("DHA") has a chain length of 22 carbons with 6 double bonds beginning with the third carbon from the methyl end and is thus designated "22:6 n-3". Other important LC-PUFAs are the fatty acids that are precursors in these biosynthetic pathways o f AA and DHA, for example, linoleic (18:2 n-6), γ-linolenic (18:3 n- 6), and dihomo-γ-linolenic (20:3 n-6) acids in the n-6 pathway, and α-linolenic (18:3 n-3), stearidonic (18:4 n-3), eicosatetraenoic (20:4 n-3), eicosapentaenoic (20:5 n-3), and docosapentaenoic (22:6 n-3) in the n-3 pathway. Less prevalent LC-PUFAs are known and listed in Tables I and TV of Carlson et al., U.S. Patent No. 6,080,787 and Table XI of Jensen (pp. 509), which are incorporated by reference. The most preferred LC-PUFAs are the 20 and 22 carbon metabolites, and in particular AA and DHA. Fatty acids are often found in nature as acyl radicals esterified to alcohols. A glyceride is such an ester of one or more fatty acids with glycerol (1,2,3-propanetriol). If only one position of the glycerol backbone molecule is esterified with a fatty acid, a "mono glyceride" is produced; if two positions are esterified, a "diglyceride" is produced; and if all three positions of the glycerol are esterified with fatty acid a "triglyceride" or "triacylglycerol" is produced. A glyceride is called "simple" if all esterified positions contain the same fatty acid; or "mixed" if different fatty acids are involved. A phospholipid (also called a "phosphoglyceride" or "phosphatide") is a special type of glyceride. A phosphoglyceride differs from a triglyceride in having a maximum of two esterified fatty acids, while the third position of the glycerol backbone is esterified to phosphoric acid, becoming a "phosphatidic acid". In nature, phosphatidic acid is usually associated with an alcohol which contributes a strongly polar head. Two such alcohols commonly found in nature are choline and enthanolamine. A "lecithin" is a phosphatidic acid associated with the aminoalcohol, "choline", and is also known as "phosphatidylcholine". Lecithins vary in the content of the fatty acid component and can be sourced from, for example, eggs and soy. Cephalin (phosphatidylethanolamine), phosphatidylserine and phosphatidylinositol are other phosphoglycerides. Triglycerides and phospholipids are often classified as long chain or medium chain, according to the fatty acids attached thereto. In human milk, about 98% of the fatty acids are in triglycerides. A source of fatty acids may include any of these forms of glycerides from natural or other origins. Sources of LC-PUFAs include dairy products like eggs and butterfat; marine oils, such as cod, menhaden, sardine, tuna and many other fish; certain animal fats, lard, tallow and microbial oils such as fungal and algal oils as described in detail in U.S. Pat. No. 5,374,657, 5,550,156, and 5,658,767. Notably, fish oils are a good source of DHA and they are commercially available in "high EPA" and "low EPA" varieties, the latter having a high DHA:EPA ratio, preferably at least 3:1. Algal oils such as those from dinoflagellates of the class Dinophyceae, notably Crypthecodinium cohnii are also sources of DHA (including DHASCO.TM.), as taught in U.S. Pat. Nos. 5,397,591, 5,407,957, 5,492,938, and 5,711,983. The genus Mortierella, especially M. alpina, and Pythium insidiosum are good sources of AA, including ARASCO as taught by U.S. Pat. No. 5,658,767 and as taught by Yamada, et al. J. Dispersion Science and Technology, 10(4&5), pp. 561-579 (1989), and Shirunen, et al. Appl. Microbiol. Biotechnol. 31:11-16 (1989). Of course, new sources of LC-PUFAs may be developed through the genetic manipulation of other organisms, particularly vegetables and/or oil bearing plants. Desaturase and elongase genes have been identified from many organisms and these might be engineered into plant or other host cells to cause them to produce large quantities of LC-PUFA- containing oils at low cost. The use of such recombinant oils are also contemplated in the present invention. The LC-PUFAs may be provided in the composition in the form of esters of free fatty acids; mono-, di- and tri-glycerides; phosphoglycerides, including lecithins; and/or mixtures thereof. It may be preferable to provide LC-PUFAs in the form of phospho lipids, especially phosphatidylcholine. A presently preferred source, at least when processed such that the organoleptic properties and cholesterol level are acceptable, appears to be egg yolk phospholipids, perhaps due to the high phospholipid and/or phosphatidylcholine content associated with egg derived LC-PUFAs. The infant formula of the present invention includes a source of LC-PUFAs that are within the range of human milk. The LC-PUFAs preferably comprise between about 4.5 to 15% by weight of total fatty acids, and comprise about 35 to 560 mg/dL. Even more preferably, the amount of LC-PUFAs in the n-6 pathway and the and n-3 pathway are within the range of human milk. The amount of LC-PUFAs in the n-6 pathway preferably range from about 10-15 wt% total fatty acids. In addition, the LC-PUFAs in the n-6 pathway preferably contain less than about 10-15% linoleic acid (18:2n-3) of total fatty acids, and even more preferably between about 10-12 wt%. The formula preferably contains about 150 to 450 mg/dl of LC-PUFAs in the n-6 pathway and about 20 to 80 mg/dl of LC-PUFAs in the n-3 pathway. The 20 and 22 carbon metabolites in the n-6 pathway preferably comprise of total fatty acids. The amount of LC-PUFAs in the n-3 pathway preferably range from about 0.35 to 1.5% wt% total fatty acids. The 20 and 22 carbon metabolites in the n-3 pathway preferably comprise about 0.5 to 1% of total fatty acids. The n-6 and/or n-3 LC-PUFAs may be administered in the form of an intravenous (i.e. parenteral) solution, as can choline and phosphatidylcholine. An intravenous solution will preferably contain effective amounts of the LC-PUFA, the phospholipid and/or the choline in a reasonable daily intake of parenteral solution. The exact concentration, therefore, is highly variable depending on the anticipated intake volume and is significantly more concentrated in a bolus or small-volume parenteral than in a hydrating or nutritional based parenteral product. Parenteral compositions will generally include pharmaceutically acceptable vehicles and excipients, such as buffers, preservatives, and the like. The n-6 and/or n-3 LC-PUFAs and the choline and phospholipid may alternatively be administered in the form of an enteral composition. Enteral compositions containing the long chain PUFA, choline or phospholipid may be in the form of a solution or an emulsion of active ingredient; or in a nutritional matrix comprising protein, carbohydrates, other fats, minerals and vitamins. Enteral compositions containing active components may provide either supplemental or complete nutritional support. The concentration of the LC- PUFAs in the enteral composition can range from about 0.35 to 4.0% of AA and DHA depending on the mode of administration and intended purpose. In complete nutritional formulas the concentration may be even lower if enough of the formula is administered to deliver effective amounts of the LC-PUFA. The infant formula preferably provides about 35 to 15% of its energy, and more preferably about 45 to 55% of its energy in the form of fatty acids. More preferably, the invention present comprehends an infant formula containing about 40-50 gms of lipid per liter of formula wherein the lipid comprises a blend of medium chain triglycerides and egg phospholipid. Typically, the lipid blend comprises from about 1-40 wt. %, more preferably about 5 to about 30 wt. %, of the egg phospholipid. This embodiment is specifically designed to provide LC-PUFAs selected from n-3 fatty acids and n-6 fatty acids, phospholipids, and/or choline in amounts beneficial to infants. In the most preferred embodiment, the infant formula contains amounts of AA and DHA that is with in the range of human milk. Preferably, the DHA content of the infant formula of the present invention ranges between about 0.05% to about 2.8 wt% of the total fatty acids. Even more preferably, DHA content is between 0J5 and 1.5 wt% of the total fatty acids. Still more preferably, the DHA content ranges between about 0.35 to 1.2 wt% of the total fatty acids. Preferably, the infant formula of the present invention contains about 2 to 104 mg/dL of DHA, even more preferably, about 6 to 60 mg/dL of DHA, and still more preferably about 13 to 45 mg/dL of DHA. Preferably, the AA content of the infant formula of the present invention ranges between about 0.3% to about 1.2 wt% of the total fatty acids. Even more preferably, AA content is between 0.4 and 1.0 wt% of the total fatty acids. Still more preferably, the AA content ranges between about 0.5 to 0.8 wt% of the total fatty acids. Preferably, the infant formula of the present invention contains about 11 to 44 mg/dL of AA, even more preferably, about 15 to 35 mg/dL of AA, and still more preferably about 23 to 30 mg/dL of AA. In the preferred embodiment, the fatty acid composition of the infant formula mimics that of human milk. More specifically, the formula preferably includes about 30 to 50% of the fatty acids as monounsaturated acids. Even more preferably, the formula contains about 30 to 40%) of the fatty acids as oleic acid (18:n-9). Research has suggested that the prolonged feeding of a diet enriched in polyunsaturated acids in early infancy has a significant cholesterol-lowering effect compared to monounsaturates. More specifically, infants fed formula with higher amounts of linoleic acid (18:2 n-6) have lower cholesterol than those fed formulas high in oleic acid. See Carlson et al., Effect of infant diets with different polyunsaturated to saturated fat ratios on circulating high-density lipoproteins, J Pediatr Gastroenterol Nutr. 1982;l(3):303-9; Mize et al., Lipoprotein-cholesterol responses in healthy infants fed defined diets from ages 1 to 12 months: comparison of diets predominant in oleic acid versus linoleic acid, with parallel observations in infants fed a human milk-based diet, J Lipid Res. 1995 Jun;36(6):l 178-87. Further, if the infants are preterm, they develop large amounts of an unusual fatty acid in their red blood cell membrane sphingomyelin. See Peeples et al., Effect ofLCPUFAS and age on red blood cell sphingomyelin 24:ln-9 and 24:2 of preterm infants with reference to term infants, PUFA in Infant Nutrition: Consensus and Controversies, Barcelona Spain, Program Abstracts, 1996, p. 3); Putnam et al., The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants, Am J Clin Nutr 1982;36:106-114. Thus, the present invention preferably includes a suitable balance of monounsaturated/polyunsaturated fats so that the cholesterol is not undesirably lowered. B. Sialic Acid Source The term "sialic acid" (abbreviated "Sia") refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N- acetyl-neuraminic acid (2-keto-5-acetamindo-3,5-dideoxy-D-glycero-D- galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated. A third sialic acid family member is 2-keto-3- deoxy-nonulosonic acid (KDN) (Nadano et al. (1986) J. Biol. Chem. 261: 11550-11557; Kanamori et al. (1990) J. Biol. Chem. 265: 21811-21819. Also included are 9-substituted sialic acids such as a 9-0 — C\ -C6 acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl- Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac. For review of the sialic acid family, see, e.g., Varki (1992) Glycobiology 2: 25-40; Sialic Acids: Chemistry,
Metabolism and Function, R. Schauer, Ed. (Springer-Verlag, New York (1992). The synthesis and use of sialic acid compounds in a sialylation procedure is described in, for example, international application WO 92/16640, published Oct. 1, 1992. Based on the foregoing, those skilled in the art will appreciate that sources of sialic acid include, but are not limited to free sialic acid (such as NANA), as well as sialic acid (such as NANA) complexed to oligosaccharides, glycoproteins, and gangliosides. In the preferred infant formula, the sources of sialic acid are comprised predominantly of NANA sources as opposed to other sialic acids, such as Neu5Gc. Even more preferably, NANA sources are exclusively used. Humans are the only mammalian species that do not convert NANA to NeuGc. As such, the present invention contemplates that that NANA-containing sources are most preferred. Oligosaccharides are polymers of varying number of residues, linkages, and subunits. The basic subunit is a carbohydrate monosaccharide or sugar, such as mannose, glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, and the like. The number of different possible stereoisomeric oligosaccharide chains is enormous. It has been estimated that more than 130 separate neutral and acidic compounds with from 3 to 22 sugars/molecules have been identified in human milk. The sialyated oligosaccharides of the present invention preferably include one or more of the sialic acid containing oligosaccharides listed in Table VI of Jensen, Handbook of Milk Composition (Academic Press 1995), at pp. 293-300, which is hereby incorporated by reference. The present invention can utilize sialic acid any form with sugar moieties, either naturally found or artificially formulated from simple to complex. The simplest is sialylglucose. See Carlson, Human milk nonprotein nitrogen: occurrence and possible functions, Adv Pediatr. 1985;32:43-70. Sialyllactose, which is commercially available from (MoBiTech, Germany), is most preferred. Natural sources of sialydated glycoproteins are well known to those skilled in the art based on of the functional roles of the glycoproteins themselves, e.g., bile salt- stimulated lipase (BSSL), erythropoietin (EPO) and lactoferrin as well as immunoglobulins. These biological glycoproteins are not good sources of NANA, but the sialic acid could be added to a protein source. Gangliosides are a class of glycolipids, often found in cell membranes, that consist of three elements. One or more sialic acid residues are attached to an oligosaccharide or carbohydrate core moiety, which in turn is attached to a hydrophobic lipid (ceramide) structure which generally is embedded in the cell membrane. The ceramide moiety includes a long chain base (LCB) portion and a fatty acid (FA) portion. Gangliosides, as well as other glycolipids and their structures in general, are discussed in, for example, Lehninger, Biochemistry (Worth Publishers, 1981) pp. 287-295 and Devlin, Textbook of Biochemistry (Wiley-Liss, 1992). Gangliosides are classified according to the number of monosaccharides in the carbohydrate moiety, as well as the number and location of sialic acid groups present in the carbohydrate moiety. Monosialogangliosides are given the designation "GM", disialogangliosides are designated "GD", trisialogangliosides "GT", and tetrasialogangliosides are designated "GQ". Gangliosides can be classified further depending on the position or positions of the sialic acid residue or residues bound. Further classification is based on the number of saccharides present in the oligosaccharide core, with the subscript "1" designating a ganglioside that has four saccharide residues (Gal-GalNAc-Gal-Glc-Ceramide), and the subscripts "2", "3" and "4" representing trisaccharide (GalNAc-Gal-Glc-Ceramide), disaccharide (Gal-Glc-Ceramide) and monosaccharide (Gal-Ceramide) gangliosides, respectively. GM3, GD3, and GM1 are the most preferred gangliosides of the present invention. Sources of gangliosides include deer velvet (actively growing cartilage type tissue in premature deer antlers) and gangliosides isolated from brain (mostly bovine, but theoretically any animal brain could be a source). Gangliosides are commercially available from Larodan Lipids (Sweden). Those skilled in the art will appreciate that gangliosides may also be biosynthesized. The infant formula of the present invention includes a source of sialic acid that is within the range of human milk. More specifically, the infant formula preferably comprises about 200-2300 mg/L of sialic acid, even more preferably about 400 to 700 mg/L of sialic acid, and most preferably about 500 to 600 mg/L sialic acid. The infant formula of the present invention preferably includes sialic acids complexed with oligosaccharides. The oligosaccharide-bound sialic acids preferably comprise between about 50 and 100% of the total source of sialic acids. Even more preferably, the sialic acid complexed with oligosaccharides account for about 70 to 80% of the sialic acid in the formula. The oligosaccharide-bound sialic acids preferably range between about 200 and 1800 mg/L, even more preferably about 400 to 1200 mg/L, and still most preferably about 500 to 600 mg/L. The infant formula of the present invention preferably includes sialic acids complexed with glycoproteins. The glycoprotein-bound sialic acids preferably comprise between about 10% and 50% of the total source of sialic acids. Even more preferably, the sialic acid complexed with glycoproteins account for about 20 to 30% of the sialic acid in the formula. The glycoprotein-bound sialic acid preferably ranges between about 100 to 550 mg/L, and still more preferably between about 200 to 300 mg/L. The infant formula of the present invention preferably ganglioside-bound sialic acids. The gangliosides preferably comprises between about 0% and 5% of the total source of sialic acids. Even more preferably, the gangliosides account for less than 1% of the sialic acid in the formula. The formula preferably contains less than 5 mg/L gangliosides. C.5 Cholesterol Source The present invention also includes a source of cholesterol well known to those skilled in the art. Among other things, cholesterol is found in eggs, beef tallow, dairy products, meat, poultry, fish, and shellfish. Egg yolks and organ meats (liver, kidney, sweetbread, and brain) are high in dietary cholesterol. Fish generally contains less cholesterol 10 than other meats, but some shellfish is high in cholesterol content. Sources of cholesterol also include precursors such as squalene, lanosterol, dimethylsterol, methostenol, lathosterol, and desmosterol. The infant formula of the present invention comprises about 10 to 40 mg/dl cholesterol. Even more preferably, the present invention comprises about 15 to 26 mg/dl 15 cholesterol. The synthetic infant formula of the present invention may be made de novo using methods well known to those skilled in the art. Alternatively, the infant formula may be made by modifying an existing infant formula to contain LC-PUFAs, sialic acids, and cholesterol within the range of human milk. 20 EXAMPLES Prophetic Example 1. Egg yolk cholesterol, N-acetylneuraminic acid, docosahexaenoic acid and arachidonic acid obtained from commercial sources are used in the following Examples. Those skilled in the art will appreciate that procedures for isolating cholesterol and N- 25 acetylneuraminic acid from traditional food sources exist (for example from egg yolk and mammalian milk, respectively) and could be modified to produce these components in the quantities necessary for bulk addition to infant formula as specified herein. Docosahexaenoic acid and arachidonic acid from fish, egg yolk lipids, egg yolk phospholipids and single cell oil sources are commercially available from a number of sources and are well known to those 30 skilled in the art. In this example, egg yolk cholesterol and N-acetylneuraminic acid would be added to a cows-milk-derived formula that is currently marketed and that contains at least 0.35% docosahexaenoic acid (Martek Biosciences) and 0.5% arachidonic acid (Martek Biosciences) of total fatty acids from single cell oil sources. Cholesterol would comprise 200 mg/L of formula. N-acetylneuraminic acid would be added in amounts of 500 mg/L as the free sugar. Both compounds could be added in these amounts without a need to change any other component of the currently marketed formula. Those skilled in the art will know that the marketed formula will needed to include macronutrients and other components within preferred ranges. See e.g., Table II of U.S. Patent No. US 6,306,908, which is incorporated by reference. Prophetic Example 2. In this example, egg yolk lipid is added with N-acetylneuraminic acid to a currently marketed formula with docosahexaenoic acid from the sources and amounts in Example 1. The egg yolk lipid would provide 200 mg/L of cholesterol and some arachidonic acid. A single cell source of arachidonic acid is added to achieve 0.5% of total fatty acids as arachidonic acid. Prophetic Example 3. In this example, cholesterol isolated from egg yolk and siallylactose from cows' milk would be added to a currently marketed formula that contains docosahexaenoic acid and arachidonic acid as 0.35 and 0.5% of total fatty acids, respectively. Cholesterol would contribute 200 mg/L formula and siallylactose would contribute 500 mg sialic acid/L. Lactose in the formula is decreased in the amount of lactose added via siallylactose per liter. As discussed above, human milk contains cholesterol, LC-PUFAs, and sialic acid. All three of these components are found in the plasma membranes of cells. In particular all three compounds are present in regions of the membrane known as lipid rafts. These lipid rafts are operationally defined as regions of the plasma membrane that are not soluble in detergent. These microdomains on the plasma membrane are rich in cholesterol (-50%), sphingolipids, including some gangliosides(~10-20%) and phospholipids. A variety of proteins are enriched in lipid rafts. These include caveolins, flotilins, GPI-linked proteins, low molecular weight and heterotrimeric G proteins, src family kinases, EGF receptors,, platelet- derived growth factor (PDGF) receptors, endothelin receptors, MAP kinase, protein kinase C etc. A variety of mechanisms appear to be employed for localizing proteins to lipid rafts (Pike, J. Lipid Res. 2003;44:655-667). Changes in these lipid rafts likely have both long-term and short-term consequences for the developing organism. These components likely influence the cell function, especially involving neutotransmitters, proteins involved in signal transduction, and proteins that function as enzymes in catalyzing the metabolic reactions. For example, the present invention contemplates that all three components are thought to be important for signaling between cells of different types, such as myelination of neurons by oligodendrocytes. In addition to development of the central nervous system, the present invention therefore predicts that alteration in LC-PUFAs, cholesterol in sialic acid can affect membranes in any organ or cell of the body and therefore function. For example changes in renal brush-border membrane cholesterol can suppress or promote domains. While specific embodiments have been shown and discussed, various modifications may of course be made, and the invention is not limited to the specific forms or arrangement of parts and steps described herein, except insofar as such limitations are included in the following claims. Further, it will be understood that certain features and sub- combinations are of utility and may be employed without reference to other features and sub- combinations. This is contemplated by and is within the scope of the claims.

Claims

CLAIMSI claim:
1. A synthetic infant milk formula comprising: about 35 to 560 mg/dL long-chain poly unsaturated fatty acids ("LC-PUFAs"); about 200 to 2300 mg/L sialic acids; and about 10 to 40 mg/dl of cholesterol.
2. The synthetic infant milk formula of claim 1 wherein said LC-PUFAs comprises one or more fatty acids in the n-6 pathway.
3. The synthetic infant milk formula of claim 2 wherein said LC-PUFAs comprises at least one fatty acid selected from the group consisting of γ-linolenic (18:3 n-6), and dihomo-γ-linolenic (20:3 n-6) acids.
4. The synthetic infant milk formula of claim 1 wherein said LC-PUFAs comprise about 150 to 450 mg/dl of n-6 LC-PUFAs.
5. The synthetic infant milk formula of claim 1 wherein LC-PUFAs comprises one or more fatty acids in the n-3 pathway.
6. The synthetic infant milk formula of claim 4 wherein said LC-PUFAs comprises at least one fatty acid selected from the group consisting of α-linolenic (18:3 n-3), stearidonic (18:4 n-3), eicosatetraenoic (20:4 n-3), eicosapentaenoic (20:5 n-3), and docosapentaenoic (22:6 n-3) acids.
7. The synthetic infant milk formula of claim 1 wherein said LC-PUFAs comprise about 20 to 80 mg/dl of n-3 LC-PUFAs.
8. The synthetic infant milk formula of claim 1 wherein said formula comprises DHA in an amount of about 0.05 to 2.8 wt% of total fatty acids.
9. The synthetic infant milk formula of claim 1 wherein said formula comprises DHA in an amount of about 0.35 to 1.2 wt% of total fatty acids.
10. The synthetic infant milk formula of claim 1 wherein said formula comprises AA in an amount of about 0.3 to 1.2 wt% of total fatty acids.
11. The synthetic infant milk formula of claim 1 wherein said formula comprises AA in an amount of about 0.5 to 0.8 wt% of total fatty acids.
12. The synthetic infant milk formula of claim 1 wherein said formula comprises DHA in an amount of about 0.35 to 1.2 wt% of the total fatty acids and AA in an amount of about 0.5 to 0.8 wt% of the total fatty acids.
13. The synthetic infant milk formula of claim 1 wherein said formula comprises 6 to 60 mg/dL of DHA.
14. The synthetic infant milk formula of claim 13 further comprising about 15 to 35 mg/dL of AA.
15. The synthetic infant milk formula of claim 1 wherein said LC-PUFAs preferably contain less than about 11 wt% of linoleic acid (18:2n-3) of total fatty acids.
16. The synthetic infant milk formula of claim 1 wherein said LC-PUFAs comprises egg phospholipid.
17. The synthetic infant milk formula of claim 1 wherein said sialic acids are selected from the group consisting of free N-acetyl-neuraminic acid ("NANA"), sialic acid- containing oligosaccharides, sialic acid-containing glycoproteins, and gangliosides.
18. The synthetic infant milk formula of claim 1 wherein said sialic acids are comprised of about 200 to 1800 mg/L of sialic acids bound to oligosacchardides.
19. The synthetic infant milk formula of claim 1 wherein said formula comprises about 100 to 550 mg/L of sialic acids bound to glycoproteins.
20. The synthetic infant milk formula of claim 1 wherein said formula comprises about 500 to 600 mg/L sialic acid.
21. The synthetic infant milk formula of claim 20 wherein between about 50 to 100% of said sialic acid is in the form of sialic acid bound to oligosaccharides.
22. The synthetic infant milk formula of claim 21 wherein said oligosaccharides include sialyllactose.
23. The synthetic infant milk formula of claim 1 wherein said sialic acid is exclusive derived from NANA.
24. The synthetic infant milk formula of claim 1 wherein said cholesterol is in the form of a cholesterol precursor selected from the group consisting of squalene, lanosterol, dimethylsterol, methostenol, lathosterol, and desmosterol.
25. The synthetic infant milk formula of claim 1 wherein said formula further comprises vitamins and minerals.
26. The synthetic infant milk formula of claim 1 wherein said formula is delivered parenterally.
27. The synthetic infant milk formula of claim 1 wherein said formula comprises about 10-35 g/L protein, about 20-50 g/L lipid, and about 60-110 gm/L of carbohydrate.
28. The synthetic infant milk formula of claim 1 where said LC-PUFAs comprise about 0.3 to 1.2 wt% and about 0.05 to about 2.87 wt% DHA of total fatty acids and about 400 to 700 mg/L of sialic acid, and about 15 to 26 mg/dL cholesterol.
29. A method of enhanced neurological development in an infant comprising administering the synthetic infant formula of claim 1 to said infant.
30. A method of enhancing the gastrointestinal protection of an infant comprising administering the synthetic infant formula of claim 1 to said infant.
31. A method of enhancing the immune function in an infant comprising administering the synthetic infant formula of claim 1 to said infant.
PCT/US2004/019738 2003-06-24 2004-06-21 Infant formula WO2005000040A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002530170A CA2530170A1 (en) 2003-06-24 2004-06-21 Infant formula
EP04776829A EP1643862A1 (en) 2003-06-24 2004-06-21 Infant formula
MXPA05014190A MXPA05014190A (en) 2003-06-24 2004-06-21 Infant formula.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48092203P 2003-06-24 2003-06-24
US60/480,922 2003-06-24

Publications (1)

Publication Number Publication Date
WO2005000040A1 true WO2005000040A1 (en) 2005-01-06

Family

ID=33551954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019738 WO2005000040A1 (en) 2003-06-24 2004-06-21 Infant formula

Country Status (10)

Country Link
US (1) US20040265462A1 (en)
EP (1) EP1643862A1 (en)
KR (1) KR20060030860A (en)
CN (1) CN1842277A (en)
AR (1) AR044886A1 (en)
CA (1) CA2530170A1 (en)
CL (1) CL2004001594A1 (en)
MX (1) MXPA05014190A (en)
TW (1) TW200509803A (en)
WO (1) WO2005000040A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007057090A1 (en) * 2005-11-18 2007-05-24 Farmaleis, S.L. A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer
WO2007073176A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Composition comprising a polyunsaturated fatty acid for improving membrane composition
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
WO2008005869A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Infant formulas for early brain development
WO2011121150A1 (en) 2010-03-31 2011-10-06 Vegenat, S.A. Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders
WO2011121151A1 (en) 2010-03-31 2011-10-06 Vegenat, S.A. Functional food supplement intended, in particular, for nutrition and for prevention and improvement in cases of neurological alterations, neurodegenerative alterations or cognitive disorders
US8445053B2 (en) 2005-11-04 2013-05-21 Arla Foods Amba Concentrate derived from a milk product enriched in naturally occuring sialyllactose and a process for preparation thereof
EP2836084B1 (en) 2012-04-10 2016-12-21 Hero AG A nutritional composition
EP3079497B1 (en) 2013-12-12 2019-10-23 Société des Produits Nestlé S.A. Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
EP2211629B1 (en) 2007-10-19 2020-07-08 Fonterra Co-Operative Group Limited Methods of maintaining or increasing growth or cognitive development
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US20100268658A1 (en) * 2001-05-14 2010-10-21 Prolacta Bioscience Method for collecting, testing and distributing milk
US20070203802A1 (en) * 2005-09-23 2007-08-30 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
US20070098863A1 (en) * 2005-09-23 2007-05-03 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
US20020182243A1 (en) * 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
CA2623483A1 (en) * 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
EP1962617A2 (en) * 2005-12-23 2008-09-03 N.V. Nutricia Infant nutritional compositions for preventing obesity
AU2007235419A1 (en) * 2006-04-03 2007-10-18 Advanced Bionutrition Corporation Feed formulations containing docosahexaenoic acid
US9185922B2 (en) 2006-06-02 2015-11-17 University Of Guelph Dairy product
US20070280998A1 (en) * 2006-06-02 2007-12-06 Larry Milligan Dairy product
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
CN105123950A (en) 2006-11-29 2015-12-09 普罗莱克塔生物科学公司 Human milk compositions and methods of making and using same
CN101631469B (en) 2006-12-08 2014-04-02 普罗莱克塔生物科学公司 Compositions of human lipids and methods of making and using same
CA2704345C (en) * 2007-11-01 2016-07-26 Enzymotec Ltd. Lipid mixture for infant nutrition
BRPI0821892A2 (en) * 2008-01-28 2014-10-07 Mead Johnson Nutrition Co NUTRITIONAL COMPOSITION CONTAINING DHA (DOCOSA-HEXAENOIC ACID), RUMENT ACID AND GANGLIOSIDES
EP2110027A1 (en) * 2008-04-01 2009-10-21 Nestec S.A. Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation
KR101116864B1 (en) 2008-08-01 2012-02-29 주식회사 베네비오 Composition for Preventing or Treating of Hyperlipidemia, Fatty Liver or Obesity
JP2012510476A (en) 2008-12-02 2012-05-10 プロラクタ バイオサイエンス，インコーポレイテッド Human milk permeation composition and methods of making and using
ES2570774T3 (en) * 2009-04-01 2016-05-20 Nestec Sa Use of arachidonic acid to reduce the risk of insulin resistance later in life
EA025117B1 (en) * 2010-03-12 2016-11-30 ДСМ АйПи АССЕТС Б.В. Method for improving nervous system and/or brain development of a fetus or breast-fed child
ES2875458T3 (en) 2010-12-29 2021-11-10 Abbott Lab Nutritional product for use in reducing the incidence of necrotizing enterocolitis in an infant, young child, or child
MY166945A (en) 2010-12-31 2018-07-25 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
MX338174B (en) 2010-12-31 2016-04-06 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents.
US9283240B2 (en) 2010-12-31 2016-03-15 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MY171620A (en) 2010-12-31 2019-10-21 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides
SG10201707519PA (en) 2010-12-31 2017-10-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
CA2822495C (en) 2010-12-31 2020-12-22 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
CN103501638A (en) 2010-12-31 2014-01-08 雅培制药有限公司 Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN102845536A (en) * 2011-06-27 2013-01-02 许德建 Newborn immune formula milk powder
WO2013016111A1 (en) 2011-07-22 2013-01-31 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CA2844045C (en) 2011-08-03 2018-05-08 Prolacta Bioscience, Inc. Microfiltration of human milk to reduce bacterial contamination
MX368124B (en) 2011-08-29 2019-09-19 Abbott Lab Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract.
US20140107193A1 (en) * 2011-10-14 2014-04-17 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of kaempferol and/or fisetin and uses thereof
US9351978B2 (en) * 2012-02-29 2016-05-31 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
CN114794241A (en) 2013-03-13 2022-07-29 普罗莱克塔生物科学公司 High fat human milk products
CN103478251B (en) * 2013-07-23 2015-03-25 东北农业大学 Preparation method of infant formula milk powder containing sialic acid
CN103431051A (en) * 2013-08-06 2013-12-11 东北农业大学 Dry process preparation method of sialic-acid-containing infant formula milk powder
US20150164833A1 (en) * 2013-12-17 2015-06-18 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of ursolic acid and uses thereof
WO2015095747A1 (en) 2013-12-20 2015-06-25 Abbott Laboratories Oral rehydration composition with oligosaccharides
CN105265968B (en) * 2015-08-20 2018-06-26 泰山医学院 A kind of purposes of sialic acid in triglyceride reducing beverage is prepared
MX2018001924A (en) 2015-08-27 2018-06-19 Nestec Sa Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them.
WO2017032886A1 (en) * 2015-08-27 2017-03-02 Nestec S.A. Gender specific synthetic nutritional compositions and nutritional systems comprising them
JP7356221B2 (en) 2015-12-30 2023-10-04 プロラクタ バイオサイエンス，インコーポレイテッド Human dairy products useful for pre- and post-operative care
CN105638906A (en) * 2016-01-11 2016-06-08 东北农业大学 Infant formula milk powder meeting lipid individual nutritional requirement of infant
CN107041546A (en) * 2016-02-05 2017-08-15 上海他普亚贸易有限公司 A kind of amino acid formula powder and preparation method thereof
EP3445353A1 (en) * 2016-04-18 2019-02-27 N.V. Nutricia Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis
CN109601980A (en) * 2018-11-15 2019-04-12 嘉必优生物技术（武汉）股份有限公司 A kind of PUFA soft capsule and preparation method thereof containing sialic acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
WO1996010922A1 (en) * 1994-10-05 1996-04-18 Milupa Aktiengesellschaft Mixture of phospholipid-containing fats and lcp fatty acids
JPH1099048A (en) * 1996-09-27 1998-04-21 Snow Brand Milk Prod Co Ltd Nutrition enriched composition
US20020004527A1 (en) * 2000-04-13 2002-01-10 Nancy Auestad Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs &amp; Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694640A (en) * 1952-04-22 1954-11-16 American Home Prod Food compositions
US3542560A (en) * 1967-12-06 1970-11-24 American Home Prod Infant formula with fat composition like human milk
US3798339A (en) * 1968-05-13 1974-03-19 Swift & Co Preparation of a milk substitute product
CH621048A5 (en) * 1977-04-27 1981-01-15 Nestle Sa
US4303692A (en) * 1978-11-22 1981-12-01 Gaull Gerald E Infant milk formula
US4670268A (en) * 1985-01-29 1987-06-02 Abbott Laboratories Enteral nutritional hypoallergenic formula
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US5021245A (en) * 1990-05-22 1991-06-04 Abbott Laboratories Infant formula containing a soy polysaccharide fiber source
NZ241359A (en) * 1991-01-24 1994-08-26 Martek Corp Supplementation of infant formula by the addition of at least two different polyunsaturated fatty acids obtained from at least two different microbial sources; compositions comprising such oils
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5234702A (en) * 1992-03-19 1993-08-10 Abbott Laboratories Antioxidant system for powdered nutritional products
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
PL343902A1 (en) * 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
WO1996010922A1 (en) * 1994-10-05 1996-04-18 Milupa Aktiengesellschaft Mixture of phospholipid-containing fats and lcp fatty acids
JPH1099048A (en) * 1996-09-27 1998-04-21 Snow Brand Milk Prod Co Ltd Nutrition enriched composition
US20020004527A1 (en) * 2000-04-13 2002-01-10 Nancy Auestad Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs &amp; Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CARLSON S E ET AL: "LOWER INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS FED A PRETERM FORMULA WITH EGG PHOSPHOLIPIDS", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD,, US, vol. 44, no. 4, October 1998 (1998-10-01), pages 491 - 498, XP000892677, ISSN: 0031-3998 *
CLANDININ M T ET AL: "Assessment of the Efficacious Dose of Arachidonic Acids in Preterm Infant Formulas: Fatty Acid Composition of Erythrocyte Membrane Lipids", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD,, US, vol. 6, no. 42, 1 December 1997 (1997-12-01), pages 819 - 825, XP002073828, ISSN: 0031-3998 *
DATABASE WPI Section Ch Week 199826, Derwent World Patents Index; Class B05, AN 1998-289843, XP002260878 *
KALLIO M J T ET AL: "Cholesterol and its precursors in human milk during prolonged exclusive breast-feeding.", AMERICAN JOURNAL OF CLINICAL NUTRITION 1989 CHILDREN'S HOSPITAL, SF-00290 HELSINKI, FINLAND, vol. 50, no. 4, 1989, pages 782, XP008038930 *
KATOKU Y ET AL: "Effect of the cholesterol content of a formula on the lipid compositions of plasma lipoprotins and red blood cell membranes in early infancy.", AMERICAN JOURNAL OF CLINICAL NUTRITION 1996 APPLIED ALIMENTARY TECH. RES. DEP., NUTR. SCI. INST., MEIJI MILK PRODUCTS CO. LTD., 1-21-3 SAKAE-CHO, HIGASHIMURAYAMA-SHI, TOKYO 189, JAPAN, vol. 64, no. 6, 1996, pages 871, XP008038785 *
KAWAKAMI H: "BIOLOGICAL SIGNIFICANCE OF SIALIC ACID-CONTAINING SUBSTANCES IN MILK AND THEIR APPLICATION", RECENT RESEARCH DEVELOPMENTS IN AGRICULTURAL AND BIOLOGICAL CHEMISTRY, XX, XX, 1997, pages 193 - 208, XP001064913 *
MARTIN-SOSA S ET AL: "Sialyloligosaccharides in human and bovine milk and in infant formulas: variations with the progression of lactation.", JOURNAL OF DAIRY SCIENCE 86 (1) 52-59 2003 CORRESPONDENCE (REPRINT) ADDRESS, P. HUESO, DEP. DE BIOQUIMICA Y BIOL. MOLECULAR, FAC. DE BIOL., UNIV. DE SALAMANCA, 37007 SALAMANCA, SPAIN. E-MAIL PHUESO(A)USAL.ES, 2003, XP002306242 *
SANCHEZ-DIAZ A ET AL: "A CRITICAL ANALYSIS OF TOTAL SIALIC ACID AND SIALOGLYCOCONJUGATE CONTENTS OF BOVINE MILK-BASED INFANT FORMULAS", JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, RAVEN PRESS, NEW YORK, NY, US, vol. 24, no. 4, April 1997 (1997-04-01), pages 405 - 410, XP008000726, ISSN: 0277-2116 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445053B2 (en) 2005-11-04 2013-05-21 Arla Foods Amba Concentrate derived from a milk product enriched in naturally occuring sialyllactose and a process for preparation thereof
WO2007057090A1 (en) * 2005-11-18 2007-05-24 Farmaleis, S.L. A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer
WO2007073176A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Composition comprising a polyunsaturated fatty acid for improving membrane composition
EP2342979A3 (en) * 2005-12-23 2014-02-05 N.V. Nutricia Composition for improving membrane composition and functioning of cells
US8546325B2 (en) 2005-12-23 2013-10-01 N.V. Nutricia Composition for improving membrane composition and functioning of cells
WO2007073176A3 (en) * 2005-12-23 2008-09-12 Nutricia Nv Composition comprising a polyunsaturated fatty acid for improving membrane composition
US8361530B2 (en) 2006-02-10 2013-01-29 Nestec S.A. Oligosaccharide mixture
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
WO2008005869A3 (en) * 2006-06-30 2008-03-27 Abbott Lab Infant formulas for early brain development
JP2009542227A (en) * 2006-06-30 2009-12-03 アボット・ラボラトリーズ Infant formula for early brain development
WO2008005033A1 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Infant formulas for early brain development
WO2008005869A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Infant formulas for early brain development
EP2211629B1 (en) 2007-10-19 2020-07-08 Fonterra Co-Operative Group Limited Methods of maintaining or increasing growth or cognitive development
WO2011121151A1 (en) 2010-03-31 2011-10-06 Vegenat, S.A. Functional food supplement intended, in particular, for nutrition and for prevention and improvement in cases of neurological alterations, neurodegenerative alterations or cognitive disorders
WO2011121150A1 (en) 2010-03-31 2011-10-06 Vegenat, S.A. Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders
EP2836084B1 (en) 2012-04-10 2016-12-21 Hero AG A nutritional composition
EP3175719B1 (en) 2012-04-10 2019-09-04 Hero AG A nutritional composition
EP3590358B1 (en) 2012-04-10 2021-08-11 Semper AB A nutritional composition
US11647777B2 (en) 2012-04-10 2023-05-16 Semper Ab Nutritional composition
EP3079497B1 (en) 2013-12-12 2019-10-23 Société des Produits Nestlé S.A. Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Also Published As

Publication number Publication date
US20040265462A1 (en) 2004-12-30
CN1842277A (en) 2006-10-04
CL2004001594A1 (en) 2005-05-06
KR20060030860A (en) 2006-04-11
AR044886A1 (en) 2005-10-05
TW200509803A (en) 2005-03-16
MXPA05014190A (en) 2006-07-03
CA2530170A1 (en) 2005-01-06
EP1643862A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
US20040265462A1 (en) Nutritional supplement
CN103054048B (en) Infant nutritional compositions for preventing obesity
KR20190035732A (en) Nutrition formula
Innis The colostrum-deprived piglet as a model for study of infant lipid nutrition
CA2109611A1 (en) Phospholipids
CN101384184A (en) Infant nutritional compositions for preventing obesity
TW201513797A (en) Nutritional compositions containing an enriched lipid fraction and uses thereof
EP3362061B1 (en) Infant formula with milk fat for promoting healthy growth
EP3574771B1 (en) Infant formula with special lipid architecture for promoting healthy growth
WO2018178310A1 (en) Infant formula for improved eating behaviour
AU2022204529B2 (en) Nutritional composition for improving cell membranes
Kim et al. Lipids and human milk
US20090191306A1 (en) Nutritional composition containing dha, rumenic acid, and gangliosides
JPH10262607A (en) Nutrient composition for infant
Taraszewski et al. N-6 fatty acids
EP3599895A1 (en) Infant formula for improved eating behaviour
EP3773011A1 (en) Nutritional composition for use in the prevention of dry skin
US20240180860A1 (en) Nutritional composition for improving cell membranes
NZ795279A (en) Nutritional composition for improving cell membranes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024361.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12005502312

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2530170

Country of ref document: CA

Ref document number: PA/a/2005/014190

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057024778

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004776829

Country of ref document: EP

Ref document number: 1200600109

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020057024778

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004776829

Country of ref document: EP